Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Blood Advances|January 4, 2018
The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemiaLucy C Fox, Katherine D Cummins, Ben Costello, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participantsJudith Trotman, Marion Fournier, Thierry Lamy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell LymphomaMichael Wang, David Salek, David Belada, et al.Blood|August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Naranie Shanmuganathan, John Reynolds, et al.European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.Best Practice & Research. Clinical Haematology|December 13, 2023
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes RegistryLucy C Fox, Zoe K McQuilten, Frank Firkin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE StudyDavid A Sallman, Guillermo Garcia-Manero, Naval Daver, et al.Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.Blood Advances|March 26, 2020
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AMLAnna L Brown, Peer Arts, Catherine L Carmichael, et al.Blood Advances|July 5, 2023
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41Claire C Homan, Michael W Drazer, Kai Yu, et al.Pageof 4